

Henning Willers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4281470/publications.pdf>

Version: 2024-02-01

85
papers

3,268
citations

126907

33
h-index

161849

54
g-index

85
all docs

85
docs citations

85
times ranked

4920
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	1.6	75
2	Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 265-270.	0.8	1
3	Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic. <i>JAMA Network Open</i> , 2022, 5, e224840.	5.9	3
4	Utility of Noncancerous Chest CT Features for Predicting Overall Survival and Noncancer Death in Patients With Stage I Lung Cancer Treated With Stereotactic Body Radiotherapy. <i>American Journal of Roentgenology</i> , 2022, 219, 579-589.	2.2	6
5	Recent trends of demographics and gender representation among panelists at the ASCO annual meeting.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11053-11053.	1.6	0
6	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.8	61
7	Low Rates of Chest Wall Toxicity When Individualizing the Planning Target Volume Margin in Patients With Early Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy. <i>Practical Radiation Oncology</i> , 2021, 11, e282-e291.	2.1	4
8	Targeting the DNA replication stress phenotype of KRAS mutant cancer cells. <i>Scientific Reports</i> , 2021, 11, 3656.	3.3	10
9	Racial and ethnic disparities among participants in precision oncology clinical studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3014-3014.	1.6	4
10	Baby Steps in the Right Direction: Toward a Parental Leave Policy for Gastroenterology Fellows. <i>American Journal of Gastroenterology</i> , 2021, 116, 2300-2300.	0.4	2
11	Assessment of a Contralateral Esophagusâ€“Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation. <i>JAMA Oncology</i> , 2021, 7, 910.	7.1	16
12	Alginate-based 3D cancer cell culture for therapeutic response modeling. <i>STAR Protocols</i> , 2021, 2, 100391.	1.2	2
13	Screening and Validation of Molecular Targeted Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e63-e74.	0.8	10
14	Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e38-e53.	0.8	2
15	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.8	5
16	Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. <i>JAMA Network Open</i> , 2021, 4, e2133205.	5.9	70
17	Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 166, 88-91.	0.6	8
18	Radioresistance of KRAS/TP53â€“mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. <i>International Journal of Cancer</i> , 2020, 147, 472-477.	5.1	36

#	ARTICLE	IF	CITATIONS
19	Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification. <i>Journal of Thoracic Oncology</i> , 2020, 15, e8-e10.	1.1	3
20	Modelling variable proton relative biological effectiveness for treatment planning. <i>British Journal of Radiology</i> , 2020, 93, 20190334.	2.2	35
21	Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. <i>Oncologist</i> , 2020, 25, 431-437.	3.7	27
22	Modeling Resistance and Recurrence Patterns of Combined Targeted Chemoradiotherapy Predicts Benefit of Shorter Induction Period. <i>Cancer Research</i> , 2020, 80, 5121-5133.	0.9	7
23	Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. <i>Journal of Neuro-Oncology</i> , 2020, 148, 81-88.	2.9	5
24	Mechanisms and Markers of Clinical Radioresistance. <i>Cancer Drug Discovery and Development</i> , 2020, , 63-96.	0.4	1
25	Introduction to Molecular Targeted Radiosensitizers: Opportunities and Challenges. <i>Cancer Drug Discovery and Development</i> , 2020, , 1-16.	0.4	2
26	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5561-5571.	7.0	64
27	Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. <i>Cell Reports</i> , 2019, 27, 3422-3432.e4.	6.4	42
28	Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 140, 26-33.	0.6	1
29	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. <i>Cancer Research</i> , 2019, 79, 3776-3788.	0.9	32
30	Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 134, 151-157.	0.6	23
31	Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons. <i>Radiotherapy and Oncology</i> , 2019, 136, 169-175.	0.6	18
32	Toward a New Framework for Clinical Radiation Biology. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 929-945.	2.2	8
33	Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. <i>British Journal of Radiology</i> , 2019, 92, 20180539.	2.2	12
34	A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 605-613.	2.5	14
35	A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 6082-6082.	1.6	6
36	PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. <i>Oncogene</i> , 2018, 37, 2793-2805.	5.9	42

#	ARTICLE	IF	CITATIONS
37	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	10.7	108
38	The Future of Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 329-340.	6.3	76
39	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 274-284.	0.8	50
40	Toward A variable RBE for proton beam therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 68-75.	0.6	71
41	The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8544-8544.	1.6	8
42	Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15674-e15674.	1.6	7
43	TP53 mutation status: emerging biomarker for precision radiation medicine?. <i>Oncoscience</i> , 2018, 5, 258-259.	2.2	2
44	Genomic evolution and acquired resistance to preoperative chemoradiation therapy (CRT) in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 613-613.	1.6	2
45	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , 2017, 77, 2018-2028.	0.9	80
46	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	82
47	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 362-371.	0.8	78
48	Immune-related adverse events (IRAEs) in metastatic lung cancer patients receiving PD-1/PD-L1 inhibitors and thoracic radiotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9079-9079.	1.6	2
49	Multifocal adenocarcinoma of the lung: Factors predictive for local therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20041-e20041.	1.6	1
50	Effects of Charged Particles on Human Tumor Cells. <i>Frontiers in Oncology</i> , 2016, 6, 23.	2.8	75
51	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 3138-3147.	7.0	68
52	Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. <i>Oncologist</i> , 2016, 21, 964-973.	3.7	45
53	Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 78-85.	0.8	33
54	Multi-criteria optimization achieves superior normal tissue sparing in a planning study of intensity-modulated radiation therapy for RTOG 1308-eligible non-small cell lung cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 118, 515-520.	0.6	28

#	ARTICLE	IF	CITATIONS
55	Towards an Integrated Understanding of Epidermal Growth Factor Receptor Biology for Radiation Therapy: Integrins Enter. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju440-dju440.	6.3	4
56	DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. <i>Seminars in Radiation Oncology</i> , 2015, 25, 237-250.	2.2	59
57	53BP1 promotes microhomology-mediated end-joining in G1-phase cells. <i>Nucleic Acids Research</i> , 2015, 43, 1659-1670.	14.5	56
58	Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. <i>Molecular Cancer Research</i> , 2015, 13, 713-720.	3.4	34
59	A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 803-810.	0.8	30
60	ACR Appropriateness Criteria® Induction and Adjuvant Therapy for N2 Non-small-cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 197-205.	1.3	11
61	Lung Cancer Cell Line Screen Links Fanconi Anemia/BRCA Pathway Defects to Increased Relative Biological Effectiveness of Proton Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 1081-1089.	0.8	77
62	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 296-302.	1.2	72
63	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. <i>Cancer Research</i> , 2014, 74, 2825-2834.	0.9	61
64	Multidisciplinary Management of Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 329-343.	1.5	13
65	EGFR-Activating Mutations Correlate with a Fanconi Anemia-like Cellular Phenotype That Includes PARP Inhibitor Sensitivity. <i>Cancer Research</i> , 2013, 73, 6254-6263.	0.9	35
66	ACR Appropriateness Criteria® Radiation Therapy for Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 206-213.	1.3	16
67	Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 200-207.	2.0	160
68	Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues. <i>Journal of Thoracic Oncology</i> , 2013, 8, 279-286.	1.1	46
69	Targeting Homologous Recombination Repair in Cancer. , 2012, , 119-160.		7
70	FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. <i>Cancer Letters</i> , 2011, 305, 86-93.	7.2	16
71	EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks. <i>Cancer Research</i> , 2011, 71, 6261-6269.	0.9	105
72	ATR-p53 Restricts Homologous Recombination in Response to Replicative Stress but Does Not Limit DNA Interstrand Crosslink Repair in Lung Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e23053.	2.5	18

#	ARTICLE	IF	CITATIONS
73	Fanconi Anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. <i>Cancer Letters</i> , 2010, 292, 73-79.	7.2	29
74	Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies. <i>Molecular Cancer Research</i> , 2009, 7, 1304-1309.	3.4	105
75	FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. <i>International Journal of Radiation Biology</i> , 2009, 85, 523-531.	1.8	22
76	Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. <i>Nucleic Acids Research</i> , 2008, 36, 4088-4098.	14.5	139
77	Disassembly of MDC1 Foci Is Controlled by Ubiquitin-Proteasome-dependent Degradation. <i>Journal of Biological Chemistry</i> , 2008, 283, 31608-31616.	3.4	60
78	Biomarkers and Mechanisms of FANCD2 Function. <i>Journal of Biomedicine and Biotechnology</i> , 2008, 2008, 1-8.	3.0	18
79	Introduction to Clinical Radiation Biology. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 1-24.	2.2	54
80	Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53. <i>Oncogene</i> , 2005, 24, 1663-1672.	5.9	60
81	Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair. <i>Molecular and Cellular Biology</i> , 2004, 24, 708-718.	2.3	287
82	Comment on "Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis" (I). <i>Science</i> , 2003, 302, 1894c-1894.	12.6	26
83	Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. <i>Oncogene</i> , 2000, 19, 632-639.	5.9	100
84	High-dose Radiation Therapy alone for Inoperable Non-small cell Lung Cancer: Experience with Prolonged Overall Treatment Times. <i>Acta Oncologica</i> , 1998, 37, 101-105.	1.8	14
85	Hyperfractionation: where do we stand?. <i>Radiotherapy and Oncology</i> , 1997, 43, 1-21.	0.6	61